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ABSTRACT
Fatigueisoneofthemostcommonsymptomsassociated
with cancer. Persistent fatigue can impair multiple as-
pects of daily functioning and quality of life, and pa-
tients report that treatment-related fatigue has a
greater impact than other symptoms, including pain,
nausea, and depression. Thus, management of fatigue is
recognized as an important component of care for pa-
tients with cancer. Treatment of advanced and meta-
static renal cell carcinoma (RCC) was, until recently,
limited to cytokine-based therapies, which are associ-
atedwithmodestresponseratesandsignificanttoxicity,
including high rates of treatment-related fatigue. The
paradigm for RCC treatment has shifted dramatically
inthelast5yearswiththeadventofefficacioustargeted
therapies. These agents provide the promise of better
tolerability because of their more selective mechanisms
of action. However, there is considerable variation in
the selectivity of targeted agents for RCC, and a review
of randomized clinical trials in patients with advanced
and/or metastatic disease reveals that there is consider-
able variation in the tolerability of these agents. Fatigue
remains a prominent toxicity with current targeted
therapies.Futureagentsthatshowbetterselectivityand
potency than current targeted therapies should help to
provide better efficacy and tolerability. The Oncologist
2010;15:1135–1146
INTRODUCTION
Fatigue has been estimated to affect 70%–100% of patients
treated for cancer [1]. The causes of fatigue in patients with
cancer are multifactorial and interrelated, although the pre-
cise underlying pathophysiology of the development of fa-
tigue has yet to be elucidated [2]. Fatigue can arise as a
result of the cancer itself or as a side effect of cancer treat-
ment.Thedisruptionofseveralphysiologicalandbiochem-
ical systems is proposed to influence the development of
cancer-related fatigue. Serotonin dysregulation, alterations
in muscle and ATP metabolism, hypothalamic–pituitary–
adrenal axis dysfunction, disruption of circadian rhythms,
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[2]. Comorbid conditions can also contribute to the devel-
opment of fatigue and include anemia, cachexia, depres-
sion, and sleep disorders [2]. Myelosuppression is a
commonsideeffectofmanycancertreatments,andpatients
with myelosuppression often experience fatigue as a result
of anemia [3]. Immunologic and targeted agents for cancer
may also induce hypothyroidism, which can lead to fatigue
[4, 5].
Fatigue is a multifaceted, subjective symptom [6]. Pa-
tients may associate fatigue with an overall lack of energy,
cognitive impairment, somnolence, mood disturbance, or
muscleweakness[7].Inclinicaltrials,fatigueiscommonly
graded using the National Cancer Institute Common Tox-
icityCriteria(NCI-CTC)andrangesfromgrade1,whereby
fatigue is greater than at baseline but with no impact on
daily living, to grade 4, whereby patients are bedbound or
experience severe fatigue-related disability [8]. The grad-
ing of fatigue is dependent on the functional assessment of
patients, which is typically quantified using either the East-
ern Cooperative Oncology Group (ECOG) scale or the
Karnofsky performance status scale [9]. A comparison of
these two scales is shown in Table 1 [10] and reveals that
clear differences exist. In particular, the discrete increment
for the Karnofsky scale is in contrast to the relatively broad
gradingsystememployedbytheECOGscale.Thedisparity
between these two measures may contribute to the wide
variation in reported incidence rates of fatigue observed
among clinical trials (see below).
Moderate fatigue (NCI-CTC grade 2), which is defined
asareductioninperformancestatus(byoneECOGlevelor
by 20% in Karnofsky score) or difficulties in carrying out
daily activities [8], can place a considerable burden on pa-
tientswhensymptomspersistovertime.Indeed,patientsre-
port that fatigue is the longest lasting and most intrusive
side effect of chemotherapy, persisting longer than pain,
nausea,anddepression,andhavingagreatereffectondaily
life [11]. Persistent fatigue can impair multiple aspects of
daily functioning and quality of life, including simple day-
to-day physical activities, that impact on patients’ ability to
care for themselves [11, 12]. Reduced emotional and men-
tal functioning, with feelings of hopelessness, isolation,
Table 1. Karnofsky and Eastern Cooperative Oncology Group performance scales
Status Karnofsky Grade ECOG
• Normal, no complaints 100 0 • Fully active
• Able to carry on all predisease performance without
restriction
• Able to carry on normal activities 90 1 • Restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or
sedentary nature (e.g., light housework and office
work)
• Minor signs or symptoms of disease
• Normal activity with effort 80
• Care for self 70 2 • Ambulatory and capable of all self-care but unable
to carry out any work activities • Unable to carry on normal activity or to
do active work
• Requires occasional assistance but able to
care for most of their needs
60 • Ambulatory for 50% of waking hours
• Requires considerable assistance and
frequent medical care
50 3 • Capable of only limited self-care
• Disabled 40 • Confined to bed or chair for 50% of waking hours
• Requires special care and assistance
• Severely disabled 30 4 • Completely disabled
• Although hospitalization is indicated,
death is nonimminent
• Cannot carry on any self-care
• Very sick 20 • Totally confined to bed or chair
• Hospitalization necessary
• Active supportive treatment necessary
• Moribund 10
• Dead 0 5 • Dead
Abbreviations: ECOG, Eastern Cooperative Oncology Group.
From Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.
Am J Clin Oncol 1982;5:649–655.
1136 Fatigue in Renal Cell Carcinomalack of motivation, sadness, and frustration, and negative
effects on social activities are also commonly reported [11,
12]. The onset of fatigue can have serious implications for
treatment, requiring reductions in treatment dose until
symptoms have resolved [13], which may impair the over-
all efficacy of therapeutic regimens.
Because grade 2 fatigue can impact many aspects of a
patient’sabilitytofunctiononadailybasis[11,12],thetol-
erabilityoftreatment-relatedgrade2fatiguemaybedepen-
dent on whether patients are likely to receive cancer
treatment indefinitely or for a defined time period. Patients
receiving time-limited cycles of therapy, in either the adju-
vant or palliative setting, may be more willing to endure
treatment-related grade 2 fatigue because they know these
symptoms will cease once treatment is completed. For pa-
tients receiving chronic therapy, for advanced or metastatic
disease, the aim of treatment is to control disease progres-
sion, thus maximizing quality of life. These patients are
likely to remain on treatment until near the time of death,
and,therefore,theexperienceofgrade2fatiguemaybeless
tolerable, particularly if combined with other treatment-
related toxicities. Thus, efficacious treatment modalities
that can be used long term with a low incidence of treat-
ment-related fatigue could represent attractive treatment
options for patients with advanced and or metastatic
disease.
Despite its undoubted impact, fatigue in cancer patients
isoftenunderreported,underdiagnosed,andundermanaged
[1]. This may be a result of the fact that the symptoms that
characterize fatigue—feelings of tiredness, exhaustion, de-
pression, feeling unwell, loss of motivation, and reduced
capacity for mental work [6, 14, 15]—may not be recorded
asfatigueperse.Further,thelackofamedicaltreatmentfor
fatigue is likely to contribute to its undermanagement [11].
RENAL CELL CARCINOMA:A N OVERVIEW
GLOBOCAN data from the International Agency for Re-
searchonCancershowedthat,in2002,cancerofthekidney
accounted for 1.9% of all new cases of cancer diagnosed
and was responsible for 102,000 deaths worldwide [16]. It
has been estimated that 90% of cancers of the kidney are
renal cell carcinoma (RCC), and 70%–85% of these are of
theclear-cellhistology[17–19].Approximately30%ofpa-
tientswithRCCpresentwithmetastaticdiseaseatinitialdi-
agnosis, and 40% of patients diagnosed with localized
tumors subsequently develop metastases [20, 21]. Histori-
cally, advanced metastatic RCC has been one of the most
treatment-resistant malignancies and was associated with a
5-yearsurvivalrate10%[17].However,overthepastde-
cade, this has increased to approximately 20% for meta-
static RCC [22], and, if diagnosed early enough, the
prognosis is generally good, with a 5-year survival rate of
96% if diagnosed at stage I [19].
Before 2006, treatment options for patients with meta-
static RCC were limited to cytokine-based therapies, such
as interleukin (IL)-2 and interferon (IFN)-, which are as-
sociated with modest response rates (typically 20%) and
significant toxicity [23]. Thus, there was a need for more
efficacious and better tolerated therapeutic options. Since
2006, a number of new therapies have been developed that
target and inhibit activity of the mammalian target of rapa-
mycin (mTOR) pathway—temsirolimus (Torisel; Wyeth
Pharmaceuticals, Inc., Madison, NJ [24]) and everolimus
(Afinitor; Novartis Pharmaceuticals Corporation, East
Hanover, NJ [25])—the vascular endothelial growth factor
(VEGF) pathway—bevacizumab (Avastin; Genentech,
Inc., South San Francisco, CA) [26]—or multiple tyrosine
kinasereceptors,includingVEGFreceptors(VEGFRs)and
platelet-derived growth factor receptors (PDGFRs). These
multiple tyrosine kinase receptor inhibitors (TKIs) include
sunitinib (Sutent; Pfizer, Inc., New York) [27], sorafenib
(Nexavar; Bayer Pharmaceuticals Corporation, West Ha-
ven, CT) [28], and pazopanib (Votrient; GlaxoSmith-
Kline,Philadelphia)[29].SorafenibalsoinhibitstheBRAF
and CRAF serine/threonine kinases [30].
ASSESSMENT AND MANAGEMENT STRATEGIES FOR
CANCER-RELATED FATIGUE
The National Comprehensive Cancer Network (NCCN)
guidelines define fatigue as a distressing, persistent, and
subjective sense of tiredness related to cancer or cancer
treatment that is not proportional to recent activity or usual
functioning [1]. However, there is no standard definition of
cancer-related fatigue, making consistent measurement and
estimates of prevalence difficult [31]. Furthermore, the expe-
rienceoffatigueinindividualpatientsissubjectiveandcanoc-
cur during different stages of the disease or treatment. No
specific guidelines have been developed for the assessment
and management of fatigue in RCC patients, although general
guidelines for cancer-related fatigue are available.
The lack of a consensus definition of fatigue is cou-
pled with the lack of well-validated assessment tools.
Numerous assessment tools have been developed and in-
clude unidimensional and multidimensional scales and
subscales that take into account measures of quality of
life, psychosocial adjustment, mood, or self-reported
health status [32]. A systematic review by Minton and
Stone (2009) highlighted that a substantial number of
these tools have not been well validated in cancer pa-
tients or assessed in a great number of studies [31]. Uni-
dimensional scales confer the advantage of being easy to
apply in clinical practice because of their short length
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pects of the multifactorial nature of fatigue, but their
length can hinder their clinical application [31]. Further
validationofthesetoolsinRCCpatientsisneededbefore
any scale can be recommended for routine use.
Until recently, management of treatment-related fa-
tigue was underrecognized by health care professionals.
In a survey of 379 cancer patients, 40% of patients un-
dergoing chemotherapy were not offered any treatment
or advice for reducing fatigue, whereas bed rest was rec-
ommended for 37% of patients [12]. Growing focus on
the quality of life of patients with cancer has led to a re-
evaluation of this distressing side effect. The NCCN has
developed guidelines for the standard of care of cancer-
related fatigue, which recommend that fatigue be sys-
tematically screened and assessed in all patients using
appropriate tools. When identified, fatigue should be
managedaccordingtoclinicalpracticeguidelines,which
should be initiated from the start of therapy and contin-
ued after completion of therapy, as clinically indicated
[1]. Etiologic factors that could contribute to fatigue ex-
perienced by cancer patients, such as anemia, pain, sleep
disturbances, and depression, should also be assessed,
because they are potentially treatable [32].
The NCCN advocates four types of intervention for fa-
tigue (Table 2). The first strategy is education and counseling
of the patient and family, which involves providing patients
with guidance on the physical symptoms they are likely to ex-
perience prior to starting cancer therapies, so they know what
to expect, and reassuring patients that fatigue is not a sign of
disease progression [1, 33]. General strategies, such as self-
monitoring,energyconservation,anddistractionrepresentthe
secondtypeofinterventionforfatigue,andcanalsobenefitpa-
tientsexperiencingtreatment-relatedfatigue(Table2)[1].En-
ergyconservationandmanagementstrategiesteachpatientsto
planadequateperiodsofrestandinactivityintotheirdailyrou-
tine, allowing them to maintain energy levels in order to carry
out valued tasks [32, 33].
The third type of intervention advocated by the NCCN
is nonpharmacologic. Such interventions include activity
enhancement, psychosocial interventions, attention-restor-
ing therapy, nutritional consultation, and sleep therapy [1].
Activity enhancement ranges from short periods of low-
intensity exercise to structured rehabilitation programs that
combine intensive exercise with physical training and ther-
apy[32,33].Psychosocialinterventionsincludecognitive–
behavioral therapy, motivational coaching, and education
onpatternsoffatigue,copingstrategies,andself-management
approachesthatmayenhancepatientmoralebygivingasense
of control over symptoms [32]. Pharmacologic interventions
comprise the fourth NCCN-advocated strategy and include
psychostimulants (for the treatment of depression, such as
methylphenidate and modafinil), treatment for anemia (such
as erythropoiesis-stimulating agents), and sleep medication
(Table2).Theeffectivenessofthesemanagementstrategiesin
Table 2. Interventions for patients on active treatment
Patient/family education
and counseling
General strategies for
management of fatigue
Nonpharmacologic
interventions Pharmacologic interventions
• Information about known
pattern of fatigue during
and following treatment
• Reassurance that
treatment-related fatigue
is not necessarily an
indicator of disease
progression
• Self-monitoring of fatigue
levels
• Energy conservation
• Set priorities
• Pace
• Delegate
• Schedule activities at
times of peak energy
• Labor-saving devices
• Postpone nonessential
activities
• Limit naps to 20–30
minutes so as to not
interfere with night-time
sleep quality
• Structured daily routine
• Attend to one activity at
a time
• Use distraction (e.g.,
games, music, reading,
socializing)
• Activity enhancement
• Maintain optimal level of
activity
• Consider initiation of
exercise program
• Consider referral to
rehabilitation: physical
therapy, occupational
therapy, and physical
medicine
• Psychosocial interventions
• CBT
• Stress management
• Relaxation
• Support groups
• Attention-restoring therapy
• Nutrition consultation
• CBT for sleep
• Sleep restriction
• Sleep hygiene
• Stimulus control
• Consider psychostimulants
(methylphenidate or modafenil)
after ruling out other causes of
fatigue
• Treat for anemia
• Consider sleep medication
Abbreviation: CBT, cognitive behavioral therapy.
From National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue,
Version 1.2009. Available at http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf, accessed February 19,
2010.
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evaluated in randomized controlled trials.
FATIGUE ASSOCIATED WITH THE CURRENT
TREATMENTS FOR RCC
Kinaseinhibitortherapiesaretypicallydevelopedtoinhibit
a discrete number of key tumor-sustaining targets, such as
PDGFRs,VEGFRs,andthereceptorforstemcellfactor(c-
KIT), but most have a propensity to bind to a range of off-
target kinases. The safety and tolerability of an agent is
influenced by both on- and off-target kinase binding.
Among the VEGF-targeted TKIs, most are associated with
some degree of hypertensive effect, suggesting that this is
an on-target side effect mediated by the VEGF pathway
[34]. However, off-target binding affinities vary consider-
ably among agents [35] and this variation may explain dif-
ferences in their tolerability [13, 36]. Given the fact that
these TKIs are often given chronically, unlike cytokine-
based therapies, the management of side effects that may
last over a long period of time becomes an important con-
sideration for both patients and health care professionals.
AlthoughthislimitationofsomeTKIsdoesnotapplytobe-
vacizumab or the mTOR inhibitors (temsirolimus and
everolimus), because of their different mode of action, side
effects still arise from nonspecific inhibition of the VEGF
pathway(bevacizumab)andcellcyclearrest(mTORinhib-
itors) [13, 36].
Recent clinical trials in RCC listed in Table 3 provide
insight into the efficacy of these new targeted agents, and
highlight the incidence of associated fatigue [37–40].
IFN-
Until recently, IFN- was one of the few treatment options
availableforRCCpatients.However,itisassociatedwitha
poor tolerability profile, and treatment-related fatigue is a
well-known and frequently severe side effect [4, 41]. Re-
cent clinical trials have shown that up to two thirds of pa-
tients report fatigue during IFN- therapy (Table 4), and
earlier evidence suggested that dose reduction is necessary
in 10%–40% of cases [4], making fatigue an almost inevi-
table and potentially therapeutically detrimental side effect
of IFN- treatment. The etiology of IFN- treatment–re-
lated fatigue is multifactorial, with endocrine failure, neu-
ropsychiatric disturbance, autoimmunity, and cytokine
dysregulation reported to contribute to the onset of fatigue
in these patients [4].
Bevacizumab
Bevacizumab is a monoclonal antibody that sequesters
VEGF, thereby preventing signaling through VEFGRs
[42]. Two phase III studies—the Cancer and Leukemia
Group B (CALGB) 90206 trial and the Avastin for Renal
Cell Cancer (AVOREN) trial—have evaluated the clinical
utility of bevacizumab plus IFN- versus IFN- alone in
patients with metastatic RCC [23, 43] (Table 3). The pro-
gression-free survival (PFS) interval was significantly
longerwithbevacizumabplusIFN-thanwithIFN-alone
in both studies (CALGB 90206: 8.5 months versus 5.2
months; p  .0001. AVOREN: 10.2 months versus 5.4
months; p  .0001) [23, 43].
In the CALGB 90206 trial, bevacizumab plus IFN-
was associated with significantly more grade 3 fatigue than
with IFN- alone (35% [n  127] versus 28% [n  98]),
whereas the rate of grade 4 fatigue was similar between
groups (2% [n  7] versus 2% [n  6]) [43]. The total rate
of all-grade fatigue was not reported. In contrast, the
AVOREN study found that the rates of all-grade fatigue
were 33% versus 27%, whereas the rates of grade 3 or 4 fa-
tigue were 12% and 8% for bevacizumab plus IFN- and
IFN- alone, respectively [23] (Table 4). The markedly
lower rate of grade 3 or 4 fatigue reported for patients re-
ceivingbevacizumabplusIFN-inthatstudyrelativetothe
Rini et al. [43] report (12% versus 37%) is surprising given
the similarities between the study regimens and popula-
tions. This difference may be indicative of variations in the
recordingoffatiguebetweenstudiesandsuggeststhatcom-
parison of fatigue rates between trials may not be reliable.
The study design also allowed for reduction of the
IFN- dose from 9 million international units (MIU) s.c.
three times weekly to 6 or 3 MIU in the event of IFN-
attributabletoxicity[23].Aretrospectivesubgroupanalysis
of 136 patients receiving bevacizumab plus IFN- who un-
derwent dose reduction was conducted to generate hypoth-
eses for future prospective studies. That analysis showed a
concomitant reduction in the rate of all-grade fatigue from
21% to 8% of patients after 6 weeks, with a further reduc-
tion to 1% upon complete IFN- withdrawal [44].
Sorafenib
Sorafenib,anoralmultikinaseinhibitor,isapprovedinsev-
eral countries worldwide for the treatment of advanced
RCC in patients who have failed prior IFN-– or IL-2–
based therapy or are considered unsuitable for such therapy
[28]. It targets receptor tyrosine kinases, including
VEGFR-2, VEGFR-3, PDGFR-, Flt-3, and c-KIT [30].
Sorafenib has been evaluated in several studies in pa-
tients with metastatic or advanced RCC (Table 3). In a
phase II study comparing sorafenib alone (n  97) with
IFN- alone (n  92) in first-line patients with metastatic
RCC similar efficacies were observed (5.7 months versus
5.6 months) (Table 3) [45]. Fatigue was reported by 42
(43.3%) and 39 (43.3%) patients, respectively, including
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Study Study design Population Treatments
Progression-free
survival (mos)
a Overall survival
(mos)
Bevacizumab
Rini et al. [40, 43] Phase III, randomized
study
732 patients with treatment-
naïve metastatic clear-cell
RCC
Bevacizumab (10 mg/kg i.v.
q2w) plus IFN- (9 MIU
s.c. tiw), n  369;
8.5 18.3
IFN- (9 MIU s.c. tiw),
n  363
5.2 17.4
Escudier et al. [23,
38]
Phase III, randomized,
placebo-controlled,
double-blind study
649 patients with treatment-
naïve metastatic RCC
Bevacizumab (10 mg/kg
q2w) plus IFN- (9 MIU
s.c. tiw), n  327;
10.2 23.3
Placebo plus IFN- (9 MIU
s.c. tiw), n  322
5.4 21.3
Sorafenib
Ratain et al. [46] Phase II, randomized,
placebo-controlled
202 cytokine-pretreated
patients with metastatic
Sorafenib (400 mg bid),
n  32;
24 wks NR
discontinuation study RCC Placebo, n  33 6 wks NR
Escudier et al. [45] Phase II, randomized,
open-label study
189 patients with treatment-
naïve metastatic RCC
Sorafenib (400 mg, bid),
n  97;
5.7 NR
IFN- (9 MIU s.c. tiw),
n  92
5.6 NR
Escudier et al. [37] Phase III, randomized,
placebo-controlled,
903 patients with
unresectable and/or
Sorafenib (400 mg bid),
n  451;
5.5 17.8
double-blind study metastatic RCC who had
undergone one prior
systemic therapy
Placebo, n  452 2.8 15.2
Sunitinib
Motzer et al. [39] Phase III, randomized
study
750 patients with treatment-
naïve metastatic RCC
Sunitinib (50 mg qd for 4
wks, followed by 2 wks
off treatment), n  375;
11 26.4
IFN- (3 MIU s.c. tiw)
b,
n  375
5 21.8
Pazopanib
Hutson et al. [58] Phase II, randomized,
open-label,
discontinuation study
225 patients with treatment-
naïve (n  155) or
cytokine-pretreated (n 
70) locally recurrent or
metastatic RCC
Pazopanib (800 mg qd),
n  225
51.7 wks NR
Sternberg et al. [59] Phase III, randomized,
placebo-controlled,
435 patients with treatment-
naïve (n  233) or
Pazopanib (800 mg qd),
n  290;
9.2 NR
double-blind study cytokine-pretreated (n 
202), locally advanced and/
or metastatic RCC
Placebo, n  145 4.2 NR
Temsirolimus
Hudes et al. [61] Phase III, randomized
study
626 patients with treatment-
naïve metastatic RCC
Temsirolimus (25 mg qw),
n  209;
3.8 10.9
IFN- (3 MIU s.c. tiw)
b,
n  207;
1.9 7.3
Temsirolimus (15 mg qw)
plus IFN- (3 MIU s.c.
tiw)
b, n  210
3.7 8.4
Everolimus
Motzer et al. [62] Phase III, randomized,
placebo-controlled,
410 patients with metastatic
clear-cell RCC, which had
Everolimus (10 mg qd),
n  272;
4.0 Not achieved
double-blind study progressed on sunitinib,
sorafenib, or both
Placebo, n  138 1.9 8.8
aTotal population.
bStarting dose.
Abbreviations: bid, twice daily; IFN, interferon; MIU, million international units; NR, none reported; q2w, every 2 weeks;
qd, once daily; qw, every week; RCC, renal cell carcinoma; tiw, three times weekly.
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[45] (Table 4). Sorafenib-treated patients reported fewer
kidney cancer–related symptoms than did IFN-–treated
patients (p  .015) [45]. Similarly, differences in quality of
life, time to health status deterioration, and treatment satis-
faction all favored sorafenib over IFN-.
In a phase II randomized discontinuation study, 202 pa-
tients with metastatic RCC who had undergone prior sur-
gery and/or cytokine therapy received open-label sorafenib
for 12 weeks [46]. At the end of this period, patients with
25% tumor shrinkage continued on open-label sorafenib,
patients with 25% tumor growth discontinued therapy,
and the remainder were randomized to double-blind treat-
ment with sorafenib or placebo for an additional 12 weeks.
In total, 65 patients were randomized to sorafenib (n  32)
or placebo (n  33), with results demonstrating a signifi-
cantlylongerPFSintervalinthesorafenibarmthaninthepla-
cebo arm (6.0 months versus 1.5 months; p  .0087) [46]. In
the total population, fatigue was the most common treatment-
related adverse event, reported at any grade for 73% of pa-
tients, including 6% with grade 3 or 4 fatigue (Table 4).
The phase III Treatment Approaches in Renal cancer
Global Evaluation Trial (TARGET) of patients with unre-
sectable and/or metastatic RCC who had undergone one
prior systemic therapy and were randomized to either sor-
afenib(n451)orplacebo(n452)demonstratedthatthe
PFS time was significantly longer in the sorafenib arm than
in the placebo arm (5.5 months versus 2.8 months; p 
.000001) [37]. Overall, among patients receiving sorafenib
and placebo, fatigue was experienced by 133 (29%) and 74
(16%) patients, respectively, including 14 (3%) and five
(1%)patientswithgrade3or4fatigue[37](Table4).Ofthe
216 patients who crossed over from placebo to sorafenib,
53 patients (25%) reported any-grade fatigue whereas 10
patients(5%)hadgrade3or4fatigue[37].Dosereductions
or interruptions were relatively infrequent, with only 28%
of patients receiving sorafenib having two or more such
events, compared with 22% of patients receiving placebo.
Sunitinib
Sunitinib is an orally administered multitargeted TKI of,
among others, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-,
PDGFR-, Flt-3, and c-KIT. The efficacy of sunitinib in
metastatic RCC underwent clinical evaluation in a large-
scale, randomized, phase III study that compared sunitinib
(n375)withIFN-(n375)intreatment-naïvepatients
Table 4. Incidence of fatigue in recent clinical trials in patients with renal cell carcinoma (total population)
Study Treatment arms Any grade, n (%) Grade >3, n (%)
Rini et al. (2008) [43] IFN- – 104 (30)
Bevacizumab plus IFN- – 134 (37)
Escudier et al. (2007) [23] IFN- 83 (27) 25 (8)
Bevacizumab plus IFN- 110 (33) 40 (12)
Escudier et al. (2009) [45] IFN- 39 (43) 9 (10)
Sorafenib 42 (43) 5 (5)
Ratain et al. (2006) [46] Placebo NR NR
Sorafenib 147 (73) 13 (6)
Escudier et al. (2009) [37]
a Placebo 74 (16) 5 (1)
Sorafenib 133 (29) 14 (3)
Motzer et al. (2009) [39]
a IFN- (52) (13)
Sunitinib (54) (11)
Hutson et al. (2010) [58] Placebo NR NR
Pazopanib 103 (46) 11 (5)
Sternberg et al. (2010) [59] Placebo 11 (9) 4 (2)
Pazopanib 55 (19) 7 (2)
Hudes et al. (2007) [61]
a,b IFN- (64) (26)
Temsirolimus (51) (11)
Motzer et al. (2008) [62] Placebo 22 (16) 1 (1)
Everolimus 53 (20) 8 (3)
aOnly percentages reported.
bFatigue recorded as asthenia.
Abbreviations: IFN, interferon; NR, not reported.
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was longer in the sunitinib-treated group than in those
treated with IFN- (PFS, 11 months versus 5 months; p 
.001) [39]. Fatigue was the second most common adverse
event(afterdiarrhea),reportedby54%ofpatientsonsunitinib
and by 52% of patients on IFN- [39] (Table 4). Grade 3 fa-
tigue was observed in 11% and 13% of patients, respectively.
As with the comparison between sorafenib and IFN- [45],
these studies appear to show that fatigue is still common
among patients receiving sunitinib alone.
Patient quality of life was also assessed using multiple
measures[39,47].Patientsreceivingsunitinibreportedbet-
ter quality of life scores at each cycle than those receiving
IFN-, with significant differences in the overall scores.
Patients treated with sunitinib experienced significantly
less severe symptoms of lack of energy, weight loss, bone
pain, fatigue, breathlessness, coughing, and fever than
those receiving IFN- (all p  .01). Updated results based
on the final dataset confirmed these initial findings [48].
This pivotal study used an interrupted dosing schedule
of4weeksonand2weeksofftherapy,developedtoreduce
the potential impact of the toxicities of the treatment ob-
servedinanimalmodels[49–51].Somepatientsappreciate
the 2-week interruption in sunitinib treatment, and many of
the adverse events associated with the treatment are re-
solved during the “drug holiday,” including treatment-
emergent fatigue [52, 53], which allows patients to plan/
attend activities and events that they would otherwise be
unabletoparticipatein.However,aminorityofpatientsex-
perience tumor flare while off treatment [53, 54], which
may lead to increased levels of fatigue as a consequence of
tumor growth [52].
Pazopanib
ThenewestTKItobeapprovedintheU.S.forthetreatment
of advanced RCC is pazopanib [19, 29, 55], which is also
currently undergoing phase III evaluation for the treatment
of advanced/metastatic RCC. Although pazopanib is a po-
tent inhibitor of VEGFR-2, it also shows activity against
VEGFR-1, VEGFR-3, PDGFR-, PDGFR-, and c-KIT
[56, 57]. Pazopanib showed markedly less activity against
Flt-3 kinase in vitro than sunitinib and sorafenib [56]. Flt-3
is implicated in the differentiation and proliferation of he-
matopoietic stem cells, and the lack of its inhibition has
been proposed as a rationale for the low rates of myelosup-
pression observed in clinical trials with pazopanib [56].
Pazopanib was evaluated in one phase II and one phase
III study, both in advanced and/or metastatic RCC patients
[58, 59] (Table 3). The phase II study was originally de-
signed as a randomized discontinuation trial, but was
changed to an open-label trial after a planned interim anal-
ysis gave an early indication of activity [58]. Overall, 225
patients (155 treatment naïve, 70 cytokine or bevacizumab
pretreated)receivedopen-labelpazopanib.Pazopanibdem-
onstrated promising efficacy results and was generally well
tolerated. The incidence of grade 3 or 4 fatigue was low
(5%) and fatigue/asthenia rarely led to discontinuation of
pazopanib (1% each) [58].
In the phase III study of treatment-naïve and cytokine-
pretreated RCC patients, pazopanib was clinically effica-
cious, as demonstrated by a longer PFS interval in the
overall study population (9.2 months versus 4.2 months;
p  .0001), with outcomes being influenced by prior ther-
apy (treatment naïve, 11.1 months versus 2.8 months; cyto-
kine pretreated, 7.4 months versus 4.2 months) [59]. Any-
gradefatiguewasreportedby19%ofpatients,withtherate
of grade 3 fatigue being very low (2%), and two patients in
the placebo group (versus no patients in the pazopanib
group) reported grade 4 fatigue (Table 4). Fourteen percent
of patients in the pazopanib arm discontinued study treat-
ment because of adverse events, compared with 3% of pa-
tientsintheplaceboarm.Thisstudyalsoassessedqualityof
life, the results of which showed no differences in the three
preselected health-related quality of life endpoints between
patients treated with pazopanib and those given placebo
(p  .05) at any of the five assessment time points.
Temsirolimus
Temsirolimus is a specific inhibitor of the mTOR pathway,
which is involved in cancer progression and metastasis
[60]. The efficacy and safety of temsirolimus alone, IFN-
alone,andcombinationtherapywereassessedinaphaseIII
study (Global Advanced Renal Cell Carcinoma [Global
ARCC])of626poor-riskpatientswithadvancedRCC[61].
ThemedianPFStimewasslightlylongerwithtemsirolimus
than with IFN- alone (3.8 months versus 1.9 months; p 
.001). All-grade asthenia was the most frequent adverse
event, recorded for 51% of patients (grade 3 or 4, 11%) re-
ceiving temsirolimus alone (Table 4); 64% and 26% of
IFN- only, and 62% and 28% of IFN- plus temsiroli-
mus–treated patients reported all-grade and grade 3 or 4 as-
thenia, respectively. In the temsirolimus only and IFN-
only arms, 23% and 39% of patients, respectively, under-
went at least one dose reduction. Based on these data, tem-
sirolimus is advocated as first-line treatment in metastatic
RCC patients with a poor prognosis [19].
Everolimus
To date, one randomized study of everolimus in advanced
RCC patients has been published [62]. Patients who were
refractory to sunitinib and/or sorafenib were randomized to
either everolimus (n  272) or placebo (n  138). Patients
1142 Fatigue in Renal Cell Carcinomatreated with everolimus had a significantly longer PFS in-
terval than patients given placebo (4.0 months versus 1.9
months; p  .0001) [62]. Following this finding, the inde-
pendentdatamonitoringcommitteeendedthestudyandpa-
tients who were initially randomized to placebo were
crossed over to everolimus [63]; however, median overall
survivaltimeshaveyettobereached.Analysisofthesafety
results showed that fatigue was the third most common ad-
verse event, reported by 53 (20%) and 22 (16%) patients,
respectively (Table 4), which suggests that everolimus
treatment does not have as marked an effect on patient-
reported fatigue as the treatments described above. None-
theless, fatigue was among the four most common reasons
for study discontinuation [62], suggesting that, in those pa-
tients who do experience this adverse event, the conse-
quences can include interruption of cancer treatment.
Health-related quality of life assessments showed no
significant clinically meaningful differences between
everolimus and placebo in terms of physical functioning or
global health status. Quality of life was sustained during
treatment with everolimus relative to placebo, irrespective
of the adverse effects that were experienced during the
study [62].
COMPARING RATES OF FATIGUE WITH THE
CURRENT TREATMENTS FOR RCC
Although it is tempting to speculate that some differences
do exist between targeted therapies—for example, pazo-
panib and sorafenib generally demonstrated lower rates of
severe fatigue than other treatments (Table 4)—such cross-
trial comparisons can only provide information that is use-
ful for hypothesis generation, which can only be validated
by properly conducted, prospective, randomized, con-
trolledtrials[64].Additionally,asidefromtheinherentlim-
itations associated with crosstrial comparisons, it is notable
that the incidence of fatigue associated with IFN- varied
considerably (any grade, 27%–64%; grade 3, 8%–30%)
in the randomized trials of targeted agents versus IFN-
(Table 4). This variation means that a comparison between
targeted therapies would not in any case provide any mean-
ingful information, given that there is no similar “baseline”
incidence of fatigue for IFN- among the different studies.
Therefore, head-to-head trials are essential to enable a ro-
bust comparison of targeted agents for the treatment of
RCC.Indeed,severalcomparatorphaseIIIclinicaltrialsare
currently ongoing in patients with RCC, the results of
which are much awaited.
TheCOMParingtheefficacy,sAfetyandtoleRabilityof
paZopanib (COMPARZ) versus sunitinib in first-line ad-
vanced and/or metastatic RCC trial (NCT00720941) is a
randomized,open-label,phaseIIIstudyinlocallyadvanced
and/or metastatic RCC patients [65]. Approximately 876
patients (aged 18 years with a Karnofsky performance
scale score 70%) who received no prior systemic therapy
foradvancedormetastaticRCCwillberandomizedina1:1
ratiotoreceiveeitheroralpazopanib(800mgoncedaily)or
oral sunitinib (50 mg), administered in 6-week cycles (4
weeks on treatment, followed by 2 weeks off treatment)
[65].
The REnal Cell cancer treatment with Oral RAD001
given Daily-3 (RECORD-3) trial is an open-label, multi-
center, phase II study that will assess the sequential activity
of everolimus and sunitinib in metastatic RCC patients
[66]. The study will compare the efficacy and safety of
everolimus first line followed by second-line sunitinib ver-
sus sunitinib first line followed by second-line everolimus
in 390 patients aged 18 years with a Karnofsky perfor-
mance status score 70% [66].
Similarly, a third trial will investigate the efficacy and
safetyoftemsirolimusversussorafenibassecond-linether-
apy in patients with advanced RCC who have failed first-
line sunitinib [67]. This randomized, open-label, active
control, single group trial will include approximately 480
patients aged 18 years with metastatic RCC, irrespective
ofhistologyornephrectomystatus,whoprogressedfollow-
ing first-line sunitinib therapy.
Finally,thephaseIIIAXItinibversusSorafenib(AXIS)
trialisunderwaytocompareaxitinib—anoralselectivein-
hibitorofVEGFR-1,VEGFR-2,VEGFR-3,andPDGFR—
with sorafenib in approximately 540 patients with
metastatic RCC who experienced failure on a first-line
treatment (including sunitinib, bevacizumab plus IFN-,
temsirolimus, or cytokines) [68].
NEED FOR BETTER TOLERATED THERAPIES
FOR RCC
As evidenced by the tolerability data from the studies de-
scribed previously, fatigue continues to be a significant
problem associated with the majority of available RCC
treatments, with approximately half of patients reporting
all-grade fatigue, and up to one third of patients reporting
fatigue of grade 3 or 4 in severity. Furthermore, the effec-
tiveness of the currently recommended fatigue manage-
ment strategies in RCC patients needs to be evaluated in
well-designed clinical trials.
Thereisaclearunmetneedtoimprovethemanagement
of fatigue. This improvement can be partially achieved
through the use of more efficacious screening, diagnosis,
and management strategies [1], but to make a significant
impact during treatment, the development of novel agents
with better safety profiles than the currently approved
agents for RCC is also required.
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clearly demonstrate that the majority of the currently avail-
able agents for RCC treatment are significantly limited by
theirassociationwithveryhighratesofpatient-reportedfa-
tigue, which is particularly evident for the multi-TKIs.
These agents are also frequently associated with gastroin-
testinalevents,particularlynausea(anygrade,activeversus
comparator, 7%–52% versus 4%–41%), vomiting (12%–
31% versus 4%–28%), and diarrhea (20%–63% versus
3%–20%) [23, 37, 39, 43, 45, 46, 58, 59, 61, 62], which
were more pronounced than with IFN- in head-to-head
studies [20, 45].
CONCLUSIONS
Fatigue represents one of the most common symptoms as-
sociated with cancer and its treatment. Despite its profound
detrimental effect on the daily activities and subsequent
quality of life of cancer patients, the etiology and mecha-
nisms underlying fatigue remain poorly understood. Con-
sequently, treatment options for fatigue are very limited,
with most physicians recommending to their patients meth-
ods aimed at managing fatigue.
In contrast, the options available for treating RCC pa-
tients have evolved considerably, from cytokine-based
therapies to targeted TKI agents. Nevertheless, these newer
treatmentsarestillassociatedwithsignificanttoxicities,in-
cluding fatigue. Moreover, the long-term administration of
these targeted therapies means that the management of
these side effects over time is an important consideration
for physicians and patients alike. Future TKIs that show
higher selectivity and potency than the current targeted
therapies should help to provide better efficacy and tolera-
bility.
Future research should focus on elucidating the mecha-
nisms by which fatigue occurs with different treatment mo-
dalities for RCC. More trials validating tools for the
assessment of fatigue in RCC patients are also needed.
Well-designed, adequately powered studies need to assess
the impact of fatigue on quality of life from the patient per-
spective and should fully evaluate the effectiveness of fa-
tigue management strategies.
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